ArticleJournal of diabetes investigation2026
Urinary extracellular vesicle miRNA signature reflects pancreatic islet stress in type 2 diabetes.
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionType 2 diabetes (T2D) is a progressive metabolic disorder characterized by insulin resistance and progressive β-cell dysfunction. Early detection remains critical to prevent long-term complications. Urinary extracellular vesicle (ECV) microRNAs (miRNAs) have emerged as stable, non-invasive biomarkers with the potential to reflect systemic molecular alterations associated with metabolic disease.
methodsWe analyzed previously generated urinary ECV miRNA sequencing data from a well-characterized cohort of 68 adults (40 T2D and 28 healthy controls). Differentially expressed miRNAs were identified and evaluated for diagnostic performance using receiver operating characteristic (ROC) analysis and supervised machine learning models with 10-fold cross-validation. Independent external validation was performed to assess generalizability. Cross-tissue validation was conducted using publicly available datasets from pancreatic islets, blood, liver, and adipose tissue. Predicted target genes were examined across tissues, and miRNA-mRNA interaction networks with pathway enrichment analyses were performed to explore functional relevance.
resultsForty-six miRNAs were significantly dysregulated in urinary ECVs from T2D patients compared with controls. Network bottleneck centrality analysis prioritized five key miRNAs (miR-320a, miR-16-5p, miR-125b-5p, miR-26a-5p, and miR-30c-5p). Individual miRNAs demonstrated moderate discriminatory capacity (AUC 0.73-0.81), while the combined panel improved performance (internal AUC = 0.87; external AUC = 0.86). Dysregulated urinary miRNA patterns partially mirrored expression changes in pancreatic islets and other metabolic tissues. Target gene analysis revealed tissue-specific alterations in key metabolic regulators, including PTEN, IGF1R, HMGA1, VEGFA, MCL1, CCND2, BTG2, and SMAD4.
conclusionUrinary ECV miRNAs reflect molecular alterations associated with T2D and represent promising complementary, non-invasive biomarkers with mechanistic relevance to disease progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.